JP2019513009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513009A5 JP2019513009A5 JP2018545230A JP2018545230A JP2019513009A5 JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5 JP 2018545230 A JP2018545230 A JP 2018545230A JP 2018545230 A JP2018545230 A JP 2018545230A JP 2019513009 A5 JP2019513009 A5 JP 2019513009A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immune cell
- modified immune
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 claims 10
- 102000004965 antibodies Human genes 0.000 claims 9
- 108090001123 antibodies Proteins 0.000 claims 9
- 102100007290 CD274 Human genes 0.000 claims 3
- 101710012053 CD274 Proteins 0.000 claims 3
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102100002977 CDR1 Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 102100013078 CD47 Human genes 0.000 claims 1
- 101700033237 CD47 Proteins 0.000 claims 1
- 102100019451 CD80 Human genes 0.000 claims 1
- 101700080477 CD80 Proteins 0.000 claims 1
- 102100005310 CTLA4 Human genes 0.000 claims 1
- 101700054183 CTLA4 Proteins 0.000 claims 1
- 101700079540 FAS Proteins 0.000 claims 1
- 101710004393 HAVCR2 Proteins 0.000 claims 1
- 102100016384 HAVCR2 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102100017213 LAG3 Human genes 0.000 claims 1
- 108060004270 LAG3 Proteins 0.000 claims 1
- 101710040448 TNFRSF4 Proteins 0.000 claims 1
- 102100013135 TNFRSF4 Human genes 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 101700008936 Tim8 Proteins 0.000 claims 1
- 241000424123 Trachinotus baillonii Species 0.000 claims 1
- 101710019504 XAB2 Proteins 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000000139 costimulatory Effects 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 101700068417 fol1 Proteins 0.000 claims 1
- 230000001506 immunosuppresive Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 230000002147 killing Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 101700050775 oct-1 Proteins 0.000 claims 1
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 claims 1
Claims (10)
- i)抗原レセプター、及び
ii)PD−L1を結合する抗体
を発現する、ナチュラルキラーT(NKT)細胞である改変免疫細胞。 - 前記抗体が、CD80及びPD−1の両方とのPD−L1相互作用を阻害する、請求項1に記載の改変免疫細胞。
- 前記CARが、1つ以上の共刺激ドメイン、例えばCD28,4−1BB(CD137)、ICOS、もしくはOX40(CD134)、又はそれらの機能的フラグメントそれぞれをさらに含む、請求項1に記載の改変免疫細胞。
- 前記抗原レセプターが内因性TCR又は改変TCRなどのTCRである、請求項1〜3のいずれか一項に記載の改変免疫細胞。
- 前記抗体が、Fcドメインを含まない、例えばFab、Fab’、scFab、scFv、Fvフラグメント、ナノボディ、VHH、dAb、最小認識ユニット、ダイアボディ、単鎖ダイアボディ(scDb)、BiTE、又はDARTからなる群から選択される抗体フラグメントである、請求項1〜4に記載の改変免疫細胞。
- 前記抗体が、100pM未満のKDでヒトPD−L1に結合する、請求項1〜5のいずれか一項に記載の改変免疫細胞。
- 前記抗体が、
i)配列番号6、7、及び8それぞれ、又は配列番号6、7、及び8と少なくとも90%同一性を有する配列に示される可変重鎖(VH)CDR配列CDR−H1、CDR−H2、及びCDR−H3、
ii)配列番号3、4、及び5それぞれ、又は配列番号3、4、及び5と少なくとも90%同一性を有する配列に示される可変軽鎖(VL)CDR配列CDR−L1、CDR−L2、及びCDR−L3、
を含む、請求項1〜6のいずれか一項に記載の改変免疫細胞。 - 前記抗体が、
i)配列番号2のVH配列、又は配列番号2と少なくとも90%同一性を有する配列、及び
ii)配列番号1のVH配列、又は配列番号1と少なくとも90%同一性を有する配列
を含む、請求項1〜7のいずれか一項に記載の改変免疫細胞。 - 前記抗体が、配列番号9又は配列番号9と少なくとも90%同一性を有する配列を含む、請求項1〜8のいずれか一項に記載の改変免疫細胞。
- 前記細胞が、IL−2、IL−4、IL−7、IL−12、IL−15、IL−21、及び/又はMIP−1アルファなどの1つ以上のサイトカイン、好ましくはヒトサイトカインをさらに発現し、及び/又は
トランスフォーミング増殖因子−ベータ(TGF−β)、IL−10、Fas、CD47、CTLA−4、Tim−3、LAG−3、及びそれらのリガンドなどの免疫抑制分子を標的とする1つ以上の抗体をさらに発現する、
請求項1〜9のいずれか一項に記載の改変免疫細胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022088103A JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16020057.2 | 2016-02-25 | ||
EP16020057 | 2016-02-25 | ||
PCT/US2017/019301 WO2017147383A1 (en) | 2016-02-25 | 2017-02-24 | Modified cells for immunotherapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022088103A Division JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019513009A JP2019513009A (ja) | 2019-05-23 |
JP2019513009A5 true JP2019513009A5 (ja) | 2020-04-02 |
JP7082574B2 JP7082574B2 (ja) | 2022-06-08 |
Family
ID=55446573
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018545230A Active JP7082574B2 (ja) | 2016-02-25 | 2017-02-24 | 免疫療法用改変細胞 |
JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Pd-l1に対する結合メンバー |
JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018544554A Active JP7080819B2 (ja) | 2016-02-25 | 2017-02-24 | Pd-l1に対する結合メンバー |
JP2022088103A Pending JP2022116230A (ja) | 2016-02-25 | 2022-05-30 | 免疫療法用改変細胞 |
Country Status (12)
Country | Link |
---|---|
US (3) | US20190048085A1 (ja) |
EP (3) | EP3420001B1 (ja) |
JP (3) | JP7082574B2 (ja) |
KR (2) | KR20190003938A (ja) |
CN (3) | CN116082505A (ja) |
AU (2) | AU2017223846A1 (ja) |
BR (2) | BR112018067696A2 (ja) |
CA (2) | CA3014001A1 (ja) |
ES (1) | ES2903408T3 (ja) |
RU (2) | RU2018128464A (ja) |
SG (2) | SG11201807188VA (ja) |
WO (2) | WO2017147383A1 (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
CN116082505A (zh) * | 2016-02-25 | 2023-05-09 | 细胞医学公司 | Pd-l1的结合成员 |
TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
GB201617714D0 (en) * | 2016-10-19 | 2016-11-30 | Ucl Business Plc | T Cell receptor |
US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
EP3555273B1 (en) | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
AU2018225102A1 (en) | 2017-02-21 | 2019-09-05 | Regeneron Pharmaceuticals, Inc. | Anti-PD-1 antibodies for treatment of lung cancer |
EP4317422A3 (en) | 2017-04-13 | 2024-05-01 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
US20210139557A1 (en) * | 2017-12-20 | 2021-05-13 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
US20200353004A1 (en) * | 2018-01-19 | 2020-11-12 | Miltenyi Biotec B.V. & Co. KG | Regulatory T Cell Expressing a Chimeric Antigen Receptor |
KR20210028140A (ko) | 2018-03-02 | 2021-03-11 | 씨디알-라이프 아게 | 삼중특이성 항원 결합 단백질 |
KR20210016514A (ko) * | 2018-03-29 | 2021-02-16 | 아다진 인크. | 항-pd-l1 항체 및 그의 용도 |
CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
US11945864B2 (en) | 2018-06-29 | 2024-04-02 | Y-Biologics Inc. | Monoclonal antibody specifically binding to LAG-3 and use thereof |
CN112672753A (zh) | 2018-07-09 | 2021-04-16 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
CN113272016A (zh) * | 2018-10-01 | 2021-08-17 | 阿迪塞特生物股份有限公司 | 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 |
US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
EP3866813A4 (en) | 2018-10-17 | 2022-08-03 | Senti Biosciences, Inc. | COMBINATORY CANCER IMMUNOTHERAPY |
SG11202105975SA (en) * | 2018-12-06 | 2021-07-29 | Guangdong Tcrcure Biopharma Technology Co Ltd | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
CN113195542B (zh) * | 2018-12-26 | 2024-05-24 | 南京传奇生物科技有限公司 | Cd30-结合部分、嵌合抗原受体及其用途 |
CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
JP2022523696A (ja) * | 2019-01-28 | 2022-04-26 | サイフォス、バイオサイエンシズ、インコーポレイテッド | Car細胞上の非天然nkg2d受容体に、結合した異種分子を選択的に送達する改変非天然nkg2dリガンド |
JP2022527081A (ja) * | 2019-03-26 | 2022-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t) |
CN110402892A (zh) * | 2019-04-30 | 2019-11-05 | 梁廷波 | 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法 |
CN112079924B (zh) * | 2019-06-12 | 2024-02-06 | 苏州工业园区唯可达生物科技有限公司 | Pd-l1靶向结合剂及其用途 |
MX2021015670A (es) * | 2019-07-02 | 2022-04-18 | Telix Int Pty Ltd | Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal. |
WO2021057906A1 (zh) * | 2019-09-25 | 2021-04-01 | 科济生物医药(上海)有限公司 | 表达il-15的免疫效应细胞 |
WO2021092019A1 (en) * | 2019-11-04 | 2021-05-14 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
RU2733430C1 (ru) * | 2019-11-19 | 2020-10-01 | Общество с ограниченной ответственностью «Реал Таргет» | Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами |
CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
EP4123021A4 (en) * | 2020-03-23 | 2024-05-15 | Curigin Co Ltd | STRUCTURE OF AN ONCOLYTIC VIRUS WITH BISPECIFIC NUCLEIC ACID MOLECULE |
KR20230038139A (ko) * | 2020-05-14 | 2023-03-17 | 버투오소 빈코, 인크. | 인간화 cd38 및 icam1 항체 및 이의 용도 |
WO2021252654A1 (en) * | 2020-06-11 | 2021-12-16 | Innovative Cellular Therapeutics Holdings, Ltd. | Cell/gene therapies targeting mage-a4 peptide |
CN115916828A (zh) * | 2020-06-25 | 2023-04-04 | 普洛迈博生物技术公司 | Pd-l1-特异性抗体和抗pd-l1-car-t细胞 |
AU2021376208A1 (en) * | 2020-11-04 | 2023-06-22 | Senti Biosciences, Inc. | Protein payload release |
CN112375743A (zh) * | 2020-11-20 | 2021-02-19 | 山东省医学科学院附属医院 | 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用 |
WO2022115719A1 (en) * | 2020-11-30 | 2022-06-02 | Fred Hutchinson Cancer Research Center | Pd-l1 binding peptides and peptide complexes and methods of use thereof |
CN113234152B (zh) * | 2021-06-03 | 2023-05-02 | 天津科技大学 | 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用 |
WO2023274387A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向gd2的通用型car-t细胞及其制备方法和应用 |
WO2023009891A2 (en) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Materials and methods of making or using il-23r binding proteins |
WO2023072043A1 (zh) * | 2021-10-26 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
CN116410331B (zh) * | 2021-12-31 | 2024-01-30 | 合源生物科技(天津)有限公司 | 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用 |
WO2023147564A2 (en) * | 2022-01-28 | 2023-08-03 | The University Of North Carolina At Chapel Hill | Natural killer t-cells and methods of using the same |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
ES2399617T3 (es) | 2002-05-22 | 2013-04-02 | Esbatech - A Novartis Company Llc | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas |
GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変t細胞レセプターを発現する細胞 |
WO2008083174A2 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
CA2689941C (en) | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
TWI686405B (zh) * | 2008-12-09 | 2020-03-01 | 建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
RS60033B1 (sr) | 2009-11-24 | 2020-04-30 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
ES2795023T3 (es) | 2011-09-16 | 2020-11-20 | Baylor College Medicine | Reconocimiento específico del microambiente tumoral mediante el uso de células NKT manipuladas |
BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
US9175082B2 (en) * | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
MX368513B (es) * | 2012-06-06 | 2019-10-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. |
CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
EP3013864A1 (en) | 2013-06-26 | 2016-05-04 | Numab AG | Novel antibody frameworks |
WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
ES2928000T3 (es) * | 2014-06-06 | 2022-11-14 | Memorial Sloan Kettering Cancer Center | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos |
EP3166974A1 (en) * | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
WO2016034666A1 (en) | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
WO2016049459A1 (en) | 2014-09-26 | 2016-03-31 | Baylor College Of Medicine | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
CA2965521A1 (en) | 2014-10-31 | 2016-05-06 | Baylor College Of Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
JP2018504894A (ja) | 2014-12-19 | 2018-02-22 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | キメラ抗原受容体およびその使用方法 |
GB201506642D0 (en) | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
CN116082505A (zh) * | 2016-02-25 | 2023-05-09 | 细胞医学公司 | Pd-l1的结合成员 |
-
2017
- 2017-02-24 CN CN202211150762.0A patent/CN116082505A/zh active Pending
- 2017-02-24 ES ES17711573T patent/ES2903408T3/es active Active
- 2017-02-24 BR BR112018067696A patent/BR112018067696A2/pt not_active Application Discontinuation
- 2017-02-24 RU RU2018128464A patent/RU2018128464A/ru not_active Application Discontinuation
- 2017-02-24 JP JP2018545230A patent/JP7082574B2/ja active Active
- 2017-02-24 SG SG11201807188VA patent/SG11201807188VA/en unknown
- 2017-02-24 EP EP17711573.0A patent/EP3420001B1/en active Active
- 2017-02-24 EP EP21209739.8A patent/EP4086285A1/en active Pending
- 2017-02-24 CA CA3014001A patent/CA3014001A1/en active Pending
- 2017-02-24 AU AU2017223846A patent/AU2017223846A1/en active Pending
- 2017-02-24 CA CA3014067A patent/CA3014067A1/en active Pending
- 2017-02-24 US US16/079,202 patent/US20190048085A1/en not_active Abandoned
- 2017-02-24 EP EP17710091.4A patent/EP3420000A1/en not_active Withdrawn
- 2017-02-24 JP JP2018544554A patent/JP7080819B2/ja active Active
- 2017-02-24 KR KR1020187027644A patent/KR20190003938A/ko active Search and Examination
- 2017-02-24 RU RU2018128462A patent/RU2018128462A/ru not_active Application Discontinuation
- 2017-02-24 BR BR112018067698A patent/BR112018067698A2/pt not_active Application Discontinuation
- 2017-02-24 SG SG11201807187XA patent/SG11201807187XA/en unknown
- 2017-02-24 CN CN201780012727.3A patent/CN108699153B/zh active Active
- 2017-02-24 WO PCT/US2017/019301 patent/WO2017147383A1/en active Application Filing
- 2017-02-24 US US16/079,210 patent/US11434294B2/en active Active
- 2017-02-24 CN CN201780012682.XA patent/CN108884164B/zh active Active
- 2017-02-24 KR KR1020187024673A patent/KR20180111870A/ko active Search and Examination
- 2017-02-24 WO PCT/EP2017/054367 patent/WO2017144681A1/en active Application Filing
- 2017-02-24 AU AU2017224843A patent/AU2017224843A1/en active Pending
-
2022
- 2022-05-30 JP JP2022088103A patent/JP2022116230A/ja active Pending
- 2022-08-30 US US17/823,355 patent/US20230235061A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019513009A5 (ja) | ||
JP2019525738A5 (ja) | ||
JP2019515646A5 (ja) | ||
IL299221A (en) | CD3 binding antibodies | |
JP2018520657A5 (ja) | ||
JP2020530289A5 (ja) | ||
RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
JP2019513370A5 (ja) | ||
JP2022116230A5 (ja) | ||
JP2020536543A5 (ja) | ||
HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
JP2019510733A5 (ja) | ||
JP2016533763A5 (ja) | ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
JP2019513725A5 (ja) | ||
JP2020508655A5 (ja) | ||
JP2017504578A5 (ja) | ||
JP2017522893A5 (ja) | ||
JP2018520993A5 (ja) | ||
JP2019500862A5 (ja) | ||
JP2019532017A5 (ja) | ||
JP2018508215A5 (ja) | ||
JP2018528776A5 (ja) | ||
JP2016531907A5 (ja) | ||
JP2020524000A5 (ja) | ||
JP2020525533A (ja) | 細胞により発現される生物学的活性を調節する抗体 |